John Neoptolemos

John P Neoptolemos
Born	(1951-06-30) 30 June 1951 Pano Zodeia, Cyprus
Citizenship	England
Education	Churchill College, Cambridge, University of Berlin, University of London, UCSD, University of Paris, University of Ulm
Known for	European Study Group for Pancreatic Cancer Research (ESPAC)
Medical career
Profession	Surgeon
Institutions	University of Birmingham (Dudley Road Hospital), (Queen Elizabeth Hospital), Liverpool University, University of Heidelberg (University Hospital Heidelberg)
Sub-specialties	General surgery, Oncology
Research	Pancreatic disease, Pancreatic cancer, Pancreatitis

John P. Neoptolemos 2021

John P. Neoptolemos (born June 30, 1951) is a British surgeon and professor. He is a pancreas specialist with over 75,000 scientific citations (h-index=134, in January 2021), £70m in competitive grants and has given 300 invited lectures at national and international scientific meetings. He was a British Department of Health Platinum Award holder from 2004, made a Fellow of the British Academy of Medical Sciences from 2007, a National Institute for Health Research (NIHR) Senior Fellow from 2011, and he was elected a Member of the Academia Europaea in 2019.

Early life and education

Neoptolemos was born in Pano Zodhia, Cyprus, moved to London in 1955, and attended Stamford Hill Primary School and then Owen’s Grammar School for Boys, at the Angel, Islington in North London. He was an undergraduate at the University of Cambridge (Churchill College) where he studied (1970-1973) for a double degree in Natural Sciences and Philosophy at Cambridge (Class 2.1). In 1974 he married Linda Joan Blaylock, a mathematics teacher from Newcastle-upon-Tyne. He undertook his clinical undergraduate training at Guy's Hospital, London (1973-1976). Following house jobs in London he completed his academic and clinical training in Leicester under the tutelage of Professor Sir Peter Bell, being awarded a Doctorate in Medicine in 1986 for his thesis "Effect of surgery on monocyte function in patients with colorectal cancer". In 1981 Neoptolemos became a Fellow of the Royal College of Surgeons of England. In 1985 he spent a year in San Diego, California at UCSD with Professor Alan Hofmann where he also met Professor Stephen J. Pandol for the first time. In San Diego he worked too for Babs Moossa, an international hepato-pancreatobiliary surgeon. Sadly, John later wrote Babs Moossa’s Obituary for the Royal College of Surgeons. His clinical education was completed following further surgical training with Professor Henri Bismuth in Paris and Professor Hans Beger (the leading pancreas surgeon of his generation) in Ulm. There he met Markus Büchler where he was training, together setting up the European Study for Pancreas Cancer Research (ESPAC) a few years later.

Career

In 1987 Neoptolemos was appointed Senior Lecturer in Surgery at the University of Birmingham, where he refined his clinical and research interests towards pancreatitis and pancreatic cancer. Initially he was at Dudley Road Hospital, later moving to the Queen Elizabeth Hospital. In 1990 he became a Reader and then in 1994 Professor of Surgery at the University of Birmingham. At Liverpool University he held the Chair of Surgery from 1996 before moving to Heidelberg University in October 2017. He had been head-hunted as Head of Department of Surgery to Liverpool in 1996 by the Dean, Professor Bernard Wood [subsequently the Director of the Center of Hominid Paleobiology at the Smithsonian in Washington DC] and the Vice Chancellor, Professor Philip Love (CBE) to focus on pancreas disease research with Professor Ole Petersen (CBE, FRS) for the University, and to develop the surgical services of the Royal Liverpool University Hospital by the Chairman James Fitzpatrick (CBE). Neoptolemos and Petersen successfully established the National Institutes of Health Research (NIHR) Pancreas Biomedical Research Unit from 2007, renewed again in 2012. Neoptolemos became the Director of the newly established Liverpool Clinical Trials Unit (LCTU) from 1996 and the Chairman of the Pancreas Tumour Multi-Disciplinary Team at the Royal Liverpool University Hospital from 2001. The Pancreas Unit became the largest in the UK. In 2013 it was the Health Services Journal National Award Winner. Neoptolemos was appointed Head of the new Division of Surgery and Oncology, School of Clinical Sciences in 2004 until 2010. In 2005 Neoptolemos became Head of the new School of Cancer Studies comprising the three Divisions of Surgery and Oncology, Pathology and Hematology within the Faculty of Medicine. At the direct request of the Vice Chancellor Sir Drummond Bone (FRSE, FRSA), he produced the Cancer Strategy for the University of Liverpool, which was formally endorsed by University Council in 2005. Both of the key objectives of the Strategy were achieved: the establishment of a Cancer Research UK (CRUK) Centre in Liverpool and the agreement by the NHS to move the Clatterbridge Cancer Centre onto the Royal Liverpool University Hospital Site (opened in 2020), and so create a modern comprehensive cancer centre. Neoptolemos was appointed the Owen and Ellen Evans Chair of Cancer Studies from 2006 to 2010, at the behest of the University’s largest single donor Dr David Price Evans a former medical student and Consultant Physician. From 2007 he became the Director of the Cancer Research UK Liverpool Cancer Trials Unit. He was the Convener, RAE Panel UOA2 (Cancer Studies) from 2004 and prepared the Cancer Studies return for RAE 2008. Only the top 18 Universities were returned in UOA2. The Liverpool return (of just 22 academics) showed ranking at around 14/15th, which was highly commendable given that the School of Cancer Studies had only been created in 2005. The University of Liverpool also improved its overall research ranking in the UK to 18th at this time and attained a world ranking within the top 100 universities – the highest ever achieved in the history of Liverpool. Because of RAE 2008, Liverpool enjoyed a 20 per cent increase in research funding to £39 million, and its total allocation from the Higher Education Funding Council for England for 2009 rose by 8.8 per cent to almost £115 million. Neoptolemos was Co-Director of the CRUK and NIHR Liverpool Experimental Cancer Centre from 2007 until 2012 and from then the Director of the LCTU GCP Labs. He led the successful application for a Cancer Research UK Liverpool Centre in 2008. He was Chairman of the Governance Board, of the newly created Cancer Research UK Liverpool Centre in 2009 until 2010 and then Director the Cancer Research UK Liverpool Cancer Centre from 2010 until 2013. The Cancer Research UK Liverpool Centre received the Freedom of the City of Liverpool on the 8th February 2012. This was “in recognition for its extensive research into treatment for cancer sufferers in the region and beyond”. The Ceremony included Sir Harpul Kumar the CEO of Cancer Research UK and Sir Howard Newby the VC of the University of Liverpool. The signatories to the Freedom Roll of Associations and Institutions of the City of Liverpool were the Lord Mayor, Councilor Frank Prendergast and Professor John Neoptolemos. Neoptolemos was a member of the University of Liverpool Trials Collaborative and the University of Liverpool Clinical Trials Oversight Committee from 2011 and a Member of the Liverpool Health Partners Joint Research Office Oversight Committee also from 2011.From 2011 his title changed to The Owen and Ellen Evans Chair of Surgery at the expressed wish of the donor Professor David Price Evans. In 2012 the LCTU was successful in being awarded the North West Surgical Trials Centre one of five awarded by the Royal College of Surgeons of England and Cancer Research UK. In 2014 the Cancer Research UK Liverpool Cancer Trials Unit (a major division of the LCTU) received accreditation as National Cancer Research Institute (NCRI) Cancer Trials Unit. Neoptolemos was Deputy Director of the Cancer Research UK and Liverpool Experimental Cancer Medicine Centre. In 2004 he received a Platinum Award from the Department which was continuously renewed. He was the Clinical Lead for the development of the UK Clinical Guidelines for Pancreatic Cancer of the National Institute for Clinical Excellence (NICE). John Neoptolemos has been Secretary and the President of the European Pancreas Club, as well as President of the Pancreatic Society of Great Britain and Ireland and the International Association of Pancreatology (IAP). As IAP President he developed the first ever IAP Guidelines in 2003 – on acute pancreatitis. More recently he has led on series of International Consensus Guidelines for Chronic Pancreatitis in collaboration with the International Association of Pancreatology, the American Pancreatic Association, the Japan Pancreas Society, and European Pancreatic Club. He was the Clinical Chair for the NICE Guidelines on Pancreatic Cancer (2015-2017) and is currently leading development of the joint International Consensus Guidelines on Chronic Pancreatitis, of the International Association Of Pancreatology, the European Pancreatic Club, the Japan Pancreas Society, and the American Pancreatic Association. Neoptolemos received international recognition including the Hirschberg Award for Pancreatic Cancer, American Pancreatic Association (2005); Life Time Achievement Award, European Pancreatic Club (2013); Ruth Brufsky Award for Pancreas Cancer Research (2017); and the Henry Lynch Award for Inherited Pancreas Diseases (2018).

Scientific merits

The specific areas of research of John Neoptolemos are new therapies for pancreatic cancer, pre-symptomatic diagnosis, prognostic and biological predictors of treatment response to pancreatic cancer, clinical trials of pancreatic cancer, hereditary and chronic pancreatitis and acute pancreatitis. In 1989 he was the founder of European Study for Pancreas Cancer Research (ESPAC) that has led the way for internationally collaborative pancreas cancer trials. In 1997 he established the European Registry of Hereditary Pancreatitis and Pancreatic Cancer (EUROPAC), a major resource and focus for the study of genetic pancreas diseases. In 2005 he co-founded the International Study Group for Pancreas Surgery (ISGPS) with Professors Claudio Bassi (Verona), Christos Dervenis (Athens) and Markus Büchler (Ulm). He undertook the first ever trial comparing a surgery with an endoscopic interventional technique – this was for the treatment of bile duct stones (BMJ 1987). He was also the first to establish that early intervention (endoscopic sphincterotomy) could improve the outcome of severe acute pancreatitis (Br J Surg 1988). In a key clinical study, he showed that trypsinogen activation was a very early event in human acute pancreatitis and that measurement of the levels of the trypsinogen activation peptide could predict the clinical outcome (Lancet 2000). Most notably, the ESPAC-1 trial was the first definitive trial to establish the benefit of adjuvant treatment in pancreatic cancer favoring chemotherapy (NEJM 2004) rather than chemoradiotherapy (Lancet 2001).

Awards and honors

• USA travelling award, Royal College of Surgeons of England 1984
• Rodney Smith Prize, Pancreatic Society of Great Britain and Ireland 1987
• Hunterian Professor of Surgery, Royal College of Surgeons of England 1987
• Moynihan Travelling Fellowship, Association of Surgeons of Great Britain and Ireland 1988
• Travelling Professor (USA), Royal Society of Medicine 1989
• British Council tour of Thai Medical Schools, Royal College of Surgeons of Thailand 1990
• Honorary membership of South African Gastroenterology Society 1991
• Eybers Visiting Professor, Medical School, University of Orange Free State, South Africa 1994
• Visiting Professor, Medical School, University of Hong Kong 1994
• Visiting Professor, Christchurch Medical School, University of Otago, New Zealand 1995
• External Examiner, Chinese University of Hong Kong 1996-1997
• Wilson Wang Visiting Professor, Chinese University of Hong Kong 1997
• Visiting Professor, University of Singapore 1998
• Hirschberg Award for Pancreatic Cancer, American Pancreatic Association in 2005.
• Honyman Gillespie Lecture, Edinburgh 2007
• Fellow Academy of Medical Sciences 2007
• Pearce Gould Visiting Professor, University College, London 2008
• Senior Investigator, National Institutes of Health Research (NIHR) 2011
• Honorary Fellow of the German Society of Surgery 2012
• Freedom of the City of Liverpool as Director Cancer Research UK Liverpool Centre 2012
• Lifetime Achievement Award, European Pancreatic Club 2013
• Honorary Professor of Nanjing Medical University 2014
• Honorary membership of the Hungary Society of Surgery in 2014
• Honorary Professor of the University of Nanjing 2015
• Honorary Fellow of the International Association of Surgeons, Gastroenterologists and Oncologists (IASGO) 2016
• Ruth Brufsky Award for Pancreas Cancer Research 2017
• Henry Lynch Award for Inherited Pancreas Diseases 2018
• Elected Member of the Academia Europaea 2019
• Specially Appointed Professor of the First Clinical Medical School of Nanjing Medical University 2018
• Medical Advisory Board for Pancreatic Cancer UK

Books (selection)

1. Neoptolemos JP (Ed). Cancer of the Pancreas.Clinical Gastroenterology, London, Baillière Tindall, Vol 4, No 4 1990, (pp 215)[1].
2. Lemoine N, Cooke T, Neoptolemos JP (Eds). Cancer: A Molecular Approach. Oxford, Blackwell Scientific, 1993 (pp 383).
3. Neoptolemos JP, Lemoine N (Eds). Pancreatic Cancer: Molecular & Clinical Advances. Oxford, Blackwell Scientific 1996 (pp 346)[2].
4. Beger HG, Warshaw A, Carr-Locke DL, Russell RCG, Buchler M, Neoptolemos JP, Saar M. (Eds). The Pancreas (Two Volumes). Boston, Blackwell Scientific 1998 (pp 1644).
5. Neoptolemos JP (Ed.). Acute Pancreatitis. Clinical Gastroenterology, London, Bailière Tindall 1999; Vol. 13, No. 2 (pp 152).
6. Gress TM, Neoptolemos JP, Lemoine NR, Real FX (Eds). Exocrine pancreas cancer. The European Pancreatic Cancer-Research Cooperative (PC-RC). Felsenstein CCCP, Hannover. 2005 (pp 531).
7. Neoptolemos JP and Bhutani MS. Fast Facts. Pancreas and Biliary Tree. Health Press Abingdon. 2006 (pp127).
8. Neoptolemos JP and Ghaneh P (Eds).Cancer of the Pancreas. Best Practice & Research in Clinical Gastroenterology. London, Baillière Tindall, 2006.
9. Beger HG, Warshaw A, Büchler M, Kozarek R, Lerch M, Neoptolemos JP, Shiratori K, Whitcomb D. (Eds). The Pancreas, Second Edition. Blackwell Publishing, Massachusetts, USA, 2008 (pp 1006).
10. Neoptolemos JP, Urrutia R, Abbruzzese JL, Büchler MW (Eds). Pancreatic Cancer. Springer, New York, 2010. Two Volumes (pp1335).
11. HG Beger HG, Nakao A, Neoptolemos JP, Peng SY, Sarr MG (Eds). Pancreatic Cancer, Cystic Neoplasms and Endocrine Tumors: Diagnosis and Management.Wiley Blackwell Publishers. 2018 (pp 436).
12. Beger HG, Warshaw A, Hruban R, Büchler M, Lerch M, Neoptolemos JP, Tooru Shimosegawa, Whitcomb D. (Eds). The Pancreas, Third Edition. Blackwell Publishing, Massachusetts, USA, 2018 (pp 1173).
13. Neoptolemos JP, Urrutia R, Abbruzzese JL, Büchler MW (Eds). Pancreatic Cancer. Springer, New York. Second Edition. 2018. Three Volumes (pp 1642)[3].
14. Beger HG, Warshaw A, Hruban R, Büchler M, Lerch M, Neoptolemos JP, Tooru Shimosegawa, Whitcomb D. (Eds). The Pancreas, Third Edition. The Pancreas: An Integrated Textbook of Basic Science. Chinese Edition. John Wiley & Sons Limited Chichester, West Sussex, United Kingdom. PO19 8SQ. ISBN 978-1-119-18839-1. 2019.

Outside interests

John Neoptolemos is a family man with two children and five grandchildren, passes respectably at competitive Ballroom and Latin dancing (Merrall’s Academy of Dance) and plays at Heswall Squash Club where he is a Trustee.

References (selection)

See PubMed for complete list of scientific articles.

Early Interventional Randomized Clinical Trials and Acute Pancreatitis

1. Neoptolemos JP, Carr-Locke DL, Fossard DP. Results of a prospective randomised study of pre-operative endoscopic sphincterotomy versus surgery alone for common bile duct stones. British Medical Journal 1987; 294:470-474.
2. Neoptolemos JP, Carr-Locke DL, London NJM, Bailey I, James D, Fossard DP. Results of a prospective randomized trial of ERCP and endoscopic sphincterotomy in acute gallstone pancreatitis. Lancet 1988; ii: 979-983.
3. Raraty M, Ward J, Sutton R, Neoptolemos JP, Petersen O. Calcium-dependent enzyme activation and vacuole formation in the apical granular region of pancreatic acinar cells. Proceedings of the National Academy of Sciences USA 2000; 97: 13126-13131.
4. Neoptolemos JP, Kemppainen EA, Mayer JM, Fitzpatrick JM, Raraty MGT, Slavin J, Beger H-G, Hiettaranta AJ, Puolakkainen PA. A multicentre study of early prediciton ofseverity in acute pancreatitis by urinary trypsinogen activation peptide. Lancet 2000; 355: 1955-1960.
5. Pfützer RH, Barmada MM, Brunskil APJ, Finch R, Hart PS, Neoptolemos J, Furey WF, Whitcomb DC. SPINK1/PSTI Polymorphisms act as disease modifiers in familial and idiopathic chronic pancreatitis. Gastroenterology 2000; 119: 615-623.
6. Gomatos, Ilias P.; Halloran, Christopher M.; Ghaneh, Paula; Raraty, Michael G.T.; Polydoros, Fotis; Evans, Jonathan C.; Smart, Howard L.; Yagati-Satchidanand, R.; Garry, Jo M.; Whelan, Philip A.; Hughes, Faye E.; Sutton, Robert; Neoptolemos, John P. (May 2016). "Outcomes From Minimal Access Retroperitoneal and Open Pancreatic Necrosectomy in 394 Patients With Necrotizing Pancreatitis". Annals of Surgery. 263 (5): 992–1001. doi:10.1097/SLA.0000000000001407. PMID 26501713.

EUROPAC

1. Threadgold J, Greenhalf W, Ellis I, Howes N, Lerch MM, Jansen J, Charnley R, Laugier R, Frulloni L, Attila GO, Delhaye M, Ihse I, Schaffalitzky de Muchadell OB, Andrén-Sandberg Å, Imrie CW, Martinek J, Gress TM, Mountford R, Whitcomb D, Neoptolemos JP. The N34S mutation of SPINK1 (PSTI) is associated with a familial pattern of idiopathic chronic pancreatitis but does not cause the disease. Gut 2002; 50: 675-681.
2. Howes N, Lerch MM, Greenhalf W, Stocken DD, Ellis I, Simon P, Truninger K, Ammann R, Cavallini G, Charnley RM, Uomo G, Delhaye M, Spicak J, Drumm B, Jansen J, Mountford R, Whitcomb DC, Neoptolemos JP; European Registry of Hereditary Pancreatitis and Pancreatic Cancer (EUROPAC). Clinical and genetic characteristics of hereditary pancreatitis in Europe. Clinical Gastroenterology and Hepatology 2004; 2(3):252–261.
3. McFaul CD, Greenhalf W, Earl J, Howes N, Neoptolemos JP for the European Registry of Hereditary Pancreatitis and Familial Pancreatic Cancer (EUROPAC), Kress R, Sina-Frey M, Rieder H, Hahn SA, Bartsch DK, for the German national Case Collection for Familial Pancreatic Cancer (FaPaCa). Anticipation in familial pancreatic cancer. Gut 2006; 55:252-258.
4. Grocock CJ, Rebours V, Delhaye M, Andren-Sandberg A, Weiss FU, Mountford R, Harcus M, Niemczyck E, Vitone L, Dodd S, Joergensen MT, Ammann RW, Schaffalitzky de Muckadell O, Butler JV, Burgess P, Kerr B, Charnley R, Sutton R, Raraty M, Deviere J, Whitcomb D, Neoptolemos J, Levy P, Lerch MM, Greenhalf W. The variable phenotype of the p.A16V mutation of cationic trypsinogen (PRSS1) in pancreatitis families. Gut 2010; 59: 357-63.

ESPAC Trials

1. Neoptolemos JP, Dunn JA, Moffitt DD, Almond J, Link K, Beger H, Bassi C, Falconi M, Pederzoli P, Dervenis C, Fernandez-Cruz, Lacaine F, Pap A, Spooner D, Kerr DJ, Friess H and Büchler M, for the members of the European Study Group for Pancreatic Cancer (ESPAC). ESPAC-1: A European, Randomized Controlled Study of Adjuvant Chemoradiation and Chemotherapy in Resectable Pancreatic Cancer. Lancet 2001; 358: 1576-85.
2. Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, Beger H, Fernandez-Cruz L, Dervenis C, Lacaine F, Falconi M, Pederzoli P, Pap A, Spooner D, Kerr DJ, Büchler MW for the members of the European Study Group for Pancreatic Cancer (ESPAC). A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. New England Journal of Medicine 2004; 350(12):1200-1210.
3. Carter, Ross; Stocken, Deborah D.; Ghaneh, Payla; Bramhall, Simon R.; Olah, Attila; Kelemen, Deszo; Bassi, Claudio; Friess, Helmut; Dervenis, Christo; Spry, Nigel; Büchler, Markus W.; Neoptolemos, John P.; European Study Group for Pancreatic Cancer (15 June 2009). "Longitudinal quality of life data can provide insights on the impact of adjuvant treatment for pancreatic cancer-Subset analysis of the ESPAC-1 data". International Journal of Cancer. 124 (12): 2960–2965. doi:10.1002/ijc.24270. PMID 19330830.
4. Neoptolemos JP, Stocken DD, Bassi C, Ghaneh P, Cunningham D, Goldstein D, Padbury R, Moore MJ, Gallinger S, Mariette C, Wente MN, Izbicki JR, Friess H, Lerch MM, Dervenis C, Oláh A, Butturini G, Doi R, Lind PA, Smith D, Valle JW, Palmer DH, Buckels JA, Thompson J, McKay CJ, Rawcliffe CL, Büchler MW; European Study Group for Pancreatic Cancer. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA. 2010; 304(10): 1073-81.
5. Neoptolemos JP, Moore MJ, Cox TF, Valle JW, Palmer DH, McDonald AC, Carter R, Tebbutt NC, Dervenis C, Smith D, Glimelius B, Charnley RM, Lacaine F, Scarfe AG, Middleton MR, Anthoney A, Ghaneh P, Halloran CM, Lerch MM, Oláh A, Rawcliffe CL, Verbeke CS, Campbell F, Büchler MW; European Study Group for Pancreatic Cancer.Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma. The ESPAC-3 Periampullary Cancer Randomized Trial. JAMA. 2012;308(2):147-56.
6. Greenhalf, William; Ghaneh, Paula; Neoptolemos, John P.; Palmer, Daniel H.; Cox, Trevor F.; Lamb, Richard F.; Garner, Elizabeth; Campbell, Fiona; Mackey, John R.; Costello, Eithne; Moore, Malcolm J.; Valle, Juan W.; McDonald, Alexander C.; Carter, Ross; Tebbutt, Niall C.; Goldstein, David; Shannon, Jennifer; Dervenis, Christos; Glimelius, Bengt; Deakin, Mark; Charnley, Richard M.; Lacaine, François; Scarfe, Andrew G.; Middleton, Mark R.; Anthoney, Alan; Halloran, Christopher M.; Mayerle, Julia; Oláh, Attila; Jackson, Richard; Rawcliffe, Charlotte L.; Scarpa, Aldo; Bassi, Claudio; Büchler, Markus W.; European Study Group for Pancreatic Cancer (January 2014). "Pancreatic Cancer hENT1 Expression and Survival From Gemcitabine in Patients From the ESPAC-3 Trial". JNCI. 106 (1). doi:10.1093/jnci/djt347. PMID 24301456.
7. Valle JW, Palmer D, Jackson R, Cox T, *Neoptolemos JP, Ghaneh P, Rawcliffe CL, Bassi C, Stocken DD, Cunningham D, O'Reilly D, Goldstein D, Robinson BA, Karapetis C, Scarfe A, Lacaine F, Sand J, Izbicki JR, Mayerle J, Dervenis C, Oláh A, Butturini G, Lind PA, Middleton MR, Anthoney A, Sumpter K, Carter R, Büchler MW. Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study. Journal of Clinical Oncology. 2014; 32:504-512. [*Corresponding author].
8. Kleeff, Jörg; Costello, Eithne; Jackson, Richard; Halloran, Chris; Greenhalf, William; Ghaneh, Paula; Lamb, Richard F; Lerch, Markus M; Mayerle, Julia; Palmer, Daniel; Cox, Trevor; Rawcliffe, Charlotte L; Strobel, Oliver; Büchler, Markus W; Neoptolemos, John P (September 2016). "The impact of diabetes mellitus on survival following resection and adjuvant chemotherapy for pancreatic cancer". British Journal of Cancer. 115 (7): 887–894. doi:10.1038/bjc.2016.277. PMID 27584663.
9. Neoptolemos, John P; Palmer, Daniel H; Ghaneh, Paula; Psarelli, Eftychia E; Valle, Juan W; Halloran, Christopher M; Faluyi, Olusola; O'Reilly, Derek A; Cunningham, David; Wadsley, Jonathan; Darby, Suzanne; Meyer, Tim; Gillmore, Roopinder; Anthoney, Alan; Lind, Pehr; Glimelius, Bengt; Falk, Stephen; Izbicki, Jakob R; Middleton, Gary William; Cummins, Sebastian; Ross, Paul J; Wasan, Harpreet; McDonald, Alec; Crosby, Tom; Ma, Yuk Ting; Patel, Kinnari; Sherriff, David; Soomal, Rubin; Borg, David; Sothi, Sharmila; Hammel, Pascal; Hackert, Thilo; Jackson, Richard; Büchler, Markus W; European Study Group for Pancreatic, Cancer. (March 2017). "Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial". The Lancet. 389 (10073): 1011–1024. doi:10.1016/S0140-6736(16)32409-6. PMID 28129987.
10. Ghaneh, Paula; Kleeff, Jorg; Halloran, Christopher M.; Raraty, Michael; Jackson, Richard; Melling, James; Jones, Owain; Palmer, Daniel H.; Cox, Trevor F.; Smith, Chloe J.; O’Reilly, Derek A.; Izbicki, Jakob R.; Scarfe, Andrew G.; Valle, Juan W.; McDonald, Alexander C.; Carter, Ross; Tebbutt, Niall C.; Goldstein, David; Padbury, Robert; Shannon, Jennifer; Dervenis, Christos; Glimelius, Bengt; Deakin, Mark; Anthoney, Alan; Lerch, Markus M.; Mayerle, Julia; Oláh, Attila; Rawcliffe, Charlotte L.; Campbell, Fiona; Strobel, Oliver; Büchler, Markus W.; Neoptolemos, John P.; European Study Group for Pancreatic, Cancer. (March 2019). "The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for Pancreatic Ductal Adenocarcinoma". Annals of Surgery. 269 (3): 520–529. doi:10.1097/SLA.0000000000002557. PMID 29068800.
11. Jones, Robert P.; Psarelli, Eftychia-Eirini; Jackson, Richard; Ghaneh, Paula; Halloran, Christopher M.; Palmer, Daniel H.; Campbell, Fiona; Valle, Juan W.; Faluyi, Olusola; O’Reilly, Derek A.; Cunningham, David; Wadsley, Jonathan; Darby, Suzanne; Meyer, Tim; Gillmore, Roopinder; Anthoney, Alan; Lind, Pehr; Glimelius, Bengt; Falk, Stephen; Izbicki, Jakob R.; Middleton, Gary William; Cummins, Sebastian; Ross, Paul J.; Wasan, Harpreet; McDonald, Alec; Crosby, Tom; Ting, Yuk; Patel, Kinnari; Sherriff, David; Soomal, Rubin; Borg, David; Sothi, Sharmila; Hammel, Pascal; Lerch, Markus M.; Mayerle, Julia; Tjaden, Christine; Strobel, Oliver; Hackert, Thilo; Büchler, Markus W.; Neoptolemos, John P. (1 November 2019). "Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Secondary Analysis of the ESPAC-4 Randomized Adjuvant Chemotherapy Trial". JAMA Surgery. 154 (11): 1038. doi:10.1001/jamasurg.2019.3337.

ISGPS

1. Bassi C, Butturini G, Fingerhut A, Yeo C, Izibicki J, Neoptolemos JP, Sarr M, Traverso W, Buchler M, Dervenis C for the International Study Group on Pancreatic Fistula Definition. Post-operative pancreatic fistula: an International Study Group (ISGPF) definition. Surgery 2005;138(1): 8-13.
2. Wente MN, Claudio Bassi, Christos Dervenis, Fingerhut A, Gouma DJ, Izbicki JR, Neoptolemos JP, Padbury RT, Sarr MG, Traverso LW, Yeo, CJ, Büchler MW.Delayed gastric emptying after pancreatic surgery – A suggested definition by the International Study Group of Pancreatic Surgery (ISGPS). Delayed gastric emptying (DGE) after pancreatic surgery: A suggested definition by the International Study Group of Pancreatic Surgery (ISGPS). Surgery 2007;142(5):761-8.
3. Wente MN, Veit JA,Claudio Bassi, Christos Dervenis, Fingerhut A, Gouma DJ, Izbicki JR, Neoptolemos JP, Padbury RT, Sarr MG, Traverso LW, Yeo, CJ, Büchler MW. Postpancreatectomy hemorrhage (PPH) – An International Study Group of Pancreatic Surgery (ISGPS) definition. Surgery 2007;142(1):20-5.
4. Shukla PJ, Barreto SG, Fingerhut A, Bassi C, Büchler MW, Dervenis C, Gouma D, Izbicki JR, Neoptolemos J, Padbury R, Sarr MG, Traverso W, Yeo CJ, Wente MN. Toward improving uniformity and standardization in the reporting of pancreatic anastomoses: a new classification system by the International Study Group of Pancreatic Surgery (ISGPS).Surgery. 2010;147(1):144-53.
5. Hartwig W, Vollmer CM, Fingerhut A, Yeo CJ, Neoptolemos JP, Adham M, Andrén-Sandberg A, Asbun HJ, Bassi C, Bockhorn M, Charnley R, Conlon KC, Dervenis C, Fernandez-Cruz L, Friess H, Gouma DJ, Imrie CW, Lillemoe KD, Milićević MN, Montorsi M, Shrikhande SV, Vashist YK, Izbicki JR, Büchler MW; International Study Group on Pancreatic Surgery. Extended pancreatectomy in pancreatic ductal adenocarcinoma: Definition and consensus of the International Study Group for Pancreatic Surgery (ISGPS). Surgery. 2014; 156(1):1-14.
6. Bockhorn M, Uzunoglu FG, Adham M, Imrie C, Milicevic M, Sandberg AA, Asbun HJ, Bassi C, Büchler M, Charnley RM, Conlon K, Cruz LF, Dervenis C, Fingerhutt A, Friess H, Gouma DJ, Hartwig W, Lillemoe KD, Montorsi M, Neoptolemos JP, Shrikhande SV, Takaori K, Traverso W, Vashist YK, Vollmer C, Yeo CJ, Izbicki JR; International Study Group of Pancreatic Surgery. Borderline resectable pancreatic cancer: A consensus statement by the International Study Group of Pancreatic Surgery (ISGPS). Surgery. 2014;155(6):977-88.
7. Tol JA, Gouma DJ, Bassi C, Dervenis C, Montorsi M, Adham M, Andrén-Sandberg A, Asbun HJ, Bockhorn M, Büchler MW, Conlon KC, Fernández-Cruz L, Fingerhut A, Friess H, Hartwig W, Izbicki JR, Lillemoe KD, Milicevic MN, Neoptolemos JP, Shrikhande SV, Vollmer CM, Yeo CJ, Charnley RM; International Study Group on Pancreatic Surgery. Definition of a standard lymphadenectomy in surgery for pancreatic ductal adenocarcinoma: A consensus statement by the International Study Group on Pancreatic Surgery (ISGPS). Surgery. 2014; 156(3):591-600.
8. Bassi C, Marchegiani G, Dervenis C, Sarr M, Abu Hilal M, Adam M, Allen P, Andersson R, Asbun HJ, Besselink MG, Conlon K, Del Chiaro M, Falconi M, Fernandez-Cruz L, Fernandez-Del Castillo C, Fingerhut A, Friess H, Gouma DJ, Hackert T, Izbicki J, Lillemoe KD, Neoptolemos JP, Olah A, Schulick R, Shrikhande SV, Takada T, Takaori K, Traverso W, Vollmer CR, Wolfgang CL, Yeo CJ, Salvia R, Buchler M; International Study Group on Pancreatic Surgery (ISGPS). The 2016 update of the International Study Group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 Years After. Surgery. 2017 Mar;161(3):584-591.
9. Shrikhande SV, Sivasanker M, Vollmer CM, Friess H, Besselink MG, Fingerhut A, Yeo CJ, Fernandez-delCastillo C, Dervenis C, Halloran C, Gouma DJ, Radenkovic D, Asbun HJ, Neoptolemos JP, Izbicki JR, Lillemoe KD, Conlon KC, Fernandez-Cruz L, Montorsi M, Bockhorn M, Adham M, Charnley R, Carter R, Hackert T, Hartwig W, Miao Y, Sarr M, Bassi C, Büchler MW; International Study Group of Pancreatic Surgery (ISGPS). Pancreatic anastomosis after pancreatoduodenectomy: A position statement by the International Study Group of Pancreatic Surgery (ISGPS). Surgery. 2017 May; 161(5):1221-1234.
10. Siriwardena AK, Windsor J, Zyromski N, Marchegiani G, Radenkovic D, Morgan C, Passas I, Olah A, Conlon KC, Smith M, Busch O, Baltatzis M, Besselink MG, Vollmer C, Castillo CF, Friess H, Garcea G, Burmeister S, Hackert T, Lillemoe KD, Schulick R, Shrikhande SV, Smith A, Gianotti L, Falconi M, Adams D, Adham M, Andersson R, Del Chiaro M, Devar J, Jegatheeswaran S, van Santvoort H, Khatkov I, Izbicki J, Büchler M, Neoptolemos JP, Bassi C, Dervenis C. Standards for reporting on surgery for chronic pancreatitis: a report from the International Study Group for Pancreatic Surgery (ISGPS). Surgery. 2020; 168: 101-105.
11. Miao Y, Lu Z, Yeo CJ, Vollmer CM Jr, Fernandez-Del Castillo C, Ghaneh P, Halloran CM, Kleeff J, de Rooij T, Werner J, Falconi M, Friess H, Zeh HJ, Izbicki JR, He J, Laukkarinen J, Dejong CH, Lillemoe KD, Conlon K, Takaori K, Gianotti L, Besselink MG, Del Chiaro M, Montorsi M, Tanaka M, Bockhorn M, Adham M, Oláh A, Salvia R, Shrikhande SV, Hackert T, Shimosegawa T, Zureikat AH, Ceyhan GO, Peng Y, Wang G, Huang X, Dervenis C, Bassi C, Neoptolemos JP, Büchler MW; International Study Group of Pancreatic Surgery (ISGPS). Management of the pancreatic transection plane after left (distal) pancreatectomy: Expert consensus guidelines by the International Study Group of Pancreatic Surgery (ISGPS). Surgery.

External links

• https://scienceblog.cancerresearchuk.org/2014/07/31/changing-the-future-of-pancreatic-cancer-the-espac-trials/